The Insulin-like growth factors I and II are peptides of 70 and 67 amino acids respectively which show a wide variety of biological actions on a large range of target cells. These include effects on proliferation as well as the induction and support of differentiation in many foetal and embryonic cell types. In humans the IGF-II gene is maximally active during the foetal period in specific rapidly proliferating cell types, amongst which are fibroblasts, hepatocytes, metanephric blastema cells and cells of the foetal adrenal cortex (Gray et al., 1987; Brice et al., 1989; Han et al., 1987; 1988) . Because many of these cell types are known to respond to the growth factor in 'primary culture (e.g. Hill et al., 1986; autocrine and paracrine mechanisms have been suggested as the natural mode of action in these tissues. Transcription of the IGF-II gene in the foetus is driven from a trio of distinct promoters which are used in specific ratios in different tissues (Schofield & Tate, 1987; dePagter-Holthuizen et al., 1987;  reviewed, Sussenbach, 1989) . The basis of these different ratios is unknown, but all three promoters are profoundly suppressed (50-100 fold) as development and histogenesis proceed.
In many naturally occurring and experimental neoplasms the 'foetal' promoters of IGF-II are 'reactivated'. This observation is particularly striking in the case of a group of developmental neoplasms, hepatoblastoma, embryonal nephroblastoma (Wilms' tumour), adrenocortical carcinoma and rhabdomyosarcoma (Scott et al., 1985) , but elevated expression is also seen in hepatocellular carcinoma (Su et al., 1989; Cariani et al., 1988) , leiomyoma & leiomyosarcoma (Hoppener et al., 1988; Daughaday et al., 1988) , colon carcinoma, and liposarcoma (Tricoli et al., 1986) together with fibrosarcomas (Schofield et al., 1989) . One common feature of all these tumours is that the presumed foetal counterparts of all these cell types make significant quantities of IGF-II mRNA and protein (Han et al., 1988; Hill, 1990) while their normal adult counterparts do not. In situ hybridisation analysis of human foetal kidney formation (Brice et al., 1989) 
Materials and methods
Cell culture Balb/c/3T3 fibroblasts (clone A 31) (Todaro & Green, 1963) were obtained from the Sir William Dunn School of Pathology collection, cultured in a 50/50 mixture of Alpha modified Eagles medium/Ham's F12 (Alpha/Ham) supplemented with 10% heat inactivated foetal calf serum (Seralabs) and cloned into microtiter plates by single cell picking following mitotic shake off from subconfluent cultures. Several 'parental' clones were picked on the basis of flat, 'normal looking' morphology, expanded, and one selected for infection with retrovirus supernatents. Balb/c (1-3) are sister clones, from the same bulk population, which do not express IGF-II from their own endogenous gene, Balb/c (1) is the parent clone used for infection with virus. Infection and cloning of virus carrying lines was carried out essentially as described in Boulter and Wagner, (1988) Viral constructs A human IGF-II cDNA was derived from the hepatoma cell line previously described (Schofield & Tate, 1987) . This variant cDNA contained a polymorphism in the B domain of the peptide converting glu-6 to gly-6. The cDNA was cloned into the Bgl II site of the replication defective retroviral vector pXTI (Boulter & Wagner, 1990) by linker substitution such that the IGF-II cDNA was driven from the HSV TK promotoer. Genomic and spliced genomic transcripts (marked g and sg respectively in Figure 1 ), give rise to the product of the neo gene and the TK driven transcripts to IGF-II protein. Viral genomes were transfected into the packaging line PA317, and G418r clones selected as viral producers for infection of the ecotropic packaging line Psi-2 (Mann et al., 1983) . G418' clones of psi-2 were then selected for production of retrovirus. The line used produced 0.5 x I05 cfu ml-', when titred on Balb/c fibroblasts. All cell clones infected with IGF-II carrying retrovirus used in the grafting experiments were found to be free of helper virus. Nucleic acid analysis Polyadenylylated RNA was prepared from subconfluent cultures by treatment with protease K and batch adsorbtion onto oligo dT cellulose (Pharmacia) according to Boulter & Wagner (1988) , electrophoresed on denaturing formaldehyde gels and blotted to nitrocellulose (Lehrach et al., 1977) . Filters were hybridised to an IGF-II probe derived from the parent construct. Markers were an RNA ladder purchased from BRL Ltd, and positions shown above. Provirus copy number was estimated by digestion of genomic DNA from clones with Xhol and subsequently hybridisation with the neor gene probe (Coulombe & Skup, 1986) . Control hybridisation was carried out using a mouse alpha-globin probe kindly provided by Dr Emma Whitelaw (Whitelaw et al., 1989) .
Results

Effects of expression of IGF-II in vitro
A human IGF-II cDNA was isolated from a hepatoma cell line, Hep G2, and cloned into the BglII site of the retroviral vector pXTI, as described in Materials and methods. Viral genomes were packaged in the ecotropic packaging cell line psi-2 and used to infect a cloned subline of Balb/c/3T3 fibroblasts (Balb/c (1)). G418 resistant colonies resulting were cloned and characterised, and four clones were chosen which expressed the introduced gene at different levels. does not express IGF-II from its own endogenous gene. Genomic, spliced genomic and transcripts originating from the TK promoter are marked as g, sg and TK respectively.
TK promotor, which are the only species capable of translation into IGF-II peptide, were generally low in comparison with the LTR derived genomic transcripts (see Figure 2 ), but radioimmunoassay showed that the cells with the 'sense' constructs secreted IGF-II into tissue culture supernatent ( We attempted to establish cell lines from tumours, both in the presence and absence of 800 g ml-' G418, and then analysed DNA and RNA from them. Surprisingly G418 resistant cell lines were difficult to obtain from experimental tumours whose progenitor cells were G418r. Analysis of DNA and RNA from both primary tumours and cultures established without G418 present indicated that in the major- ity of cases (35/40) the tumour cells had lost the active introduced copies of the virus (see Figure 4) . Of the remaining five cases the IGF-Il sequences were truncated in one instance, did not produce mRNA transcripts (e.g. XG7 in Figure 4 ), presumably due to point mutations, in two cases, since no change in the restriction map was evident; and unaffected in the two remaining tumours. From these results it is clear that Bal 9 is unusual in that it loses the IGF-II sequences very rapidly (see Table I ). Karyotype analysis was conducted on cell lines established from tumours in the absence of G418 selection, and demonstrated no consistent pattern of chromosome loss or gain during the latent period.
IGF-II is usually active as a secreted peptide and we wished to see if it were possible to obtain a trans-acting suppression of tumour formation by mixing equal numbers of an IGF-II expressing clone (BB4) with the antisense containing line. 5 x 106 cells of each line were inoculated suprascapularly into a single site. The results are shown in Table I , and indicate that no obvious trans acting effect could be obtained.
Discussion
It has previously been reported that Balb/c/3T3 fibroblasts require insulin-like growth factors to proliferate under conditions of serum starvation (Wharton et al., 1981) . This de- pendence is not only reflected in their rate of proliferation but also in their ability to grow in an anchorage independant fashion (Massague et al., 1985) . We confirm these findings and have demonstrated that this requirement may be abrogated by provision of endogenously synthesised peptide.
Addition of exogenous recombinant IGF-II to non-expressing cells stimulated cell proliferation markedly but seemed to be less effective than autocrine expression in sister clones in terms of nominal available concentration/cell when compared with the measured rates of secretion of IGF into the medium. This may be explained by continuous internalisation of autocrine IGF-II during growth, leading to an underestimate of the rate of production.
The three parental clones from our original population of target cells were of similar morphology, and little variability was observed in their ability to produce tumours in nude mice. This is broadly in agreement with previous studies (Rubin, 1988) (Tepper et al., 1988) . However, in contrast to the systemic effects of IL4 on tumour suppression implantation of expressing and non-expressing clones together did not result in a trans effect. This suggests a cell autonomous process such as that described by Copeman and Harris (1990) .
Identification of IGF-II as a tumour suppressor in this system is surprising because in the clinical situation levels of IGF-II mRNA are often much higher in tumours than in the surrounding adult host tissue in which they are found (Scott et al., 1985 , Su et al., 1989 Cariani et al., 1988; Hoppener et al., 1988; Daughaday et al., 1988; Tricoli et al., 1986 In sporadic Wilms' tumour , hereditary
Wilms; tumour, Beckwith-Weidemann syndrome (Ping et al., 1989) , adrenocortical carcinoma, rhabdomyosarcoma (Koufos et al., 1985) and mammary carcinoma (Ali et al., 1987 ) allele loss at llpl5.5 is frequently detected with allele specific polymorphisms in the insulin gene, and these losses are not always associated with detectable changes in the more proximal region of the short arm. (Haselbacher et al., 1987) . We propose that expression of IGF-II mRNA by developmental tumours may be a tumour epiphenomenon, as the postulated progenitor cell types, (e.g. metanephric blastema in the case of Wilms' tumour), are known to make IGF-II mRNA and protein at high levels. Selection against such expression in a cell already transformed might be expected if IGF-II has the same suppressive effect on tumour formation in man as in an experimental situation. In support of this Little et al. (1987) using xenografts of primary Wilms' tumours, were able to demonstrate that IGF-II expression was selected against during tumour passage, and they suggested that elevated IGF-II mRNA was not an essential component of tumour progression. Additionally, Maitland et al. (1989) have reported the selective loss of chromosome 11 during maintenance of cell hybrids between normal human foetal kidney and HeLa cells as grafts in nude mice. The reported occurrence of deletions in llpl3 and llpl5 in Wilms' tumours associated with aniridia (WAGR) (Henry et al., 1989) suggests that suppression of IGF-II expression may be important in tumour progression rather than in initiation, the latter perhaps being the function of the llpl3 deletion. Candidate genes in this region have recently been described (Gessler et al., 1990; Rose et al., 1990) . Current experiments are being directed towards the mechanism responsible for the tumour suppressing effect of IGF-II.
